Oral Biolife (OBL), a biotechnology firm, has announced significant progress in the development of its innovative dental treatment, Ambrilux Dental Gel. This product aims to address periodontal disease (PD) in both humans and pets. Recent studies demonstrated that the gel effectively promotes bone regeneration in the furcations of teeth in three beagles with induced periodontal disease.
Bill Breitenbach, CEO of Oral Biolife, described the findings as a “major milestone,” stating that the results bolster confidence in Ambrilux’s potential to transform dental care by offering a less invasive and more accessible treatment option.
In the study, researchers conducted radiographs at baseline, 28 days after the first application, and 29 days following a second application.
The results showed that all three treated dogs experienced increased bone regeneration at both one and two months post-treatment. In contrast, only one of three control dogs exhibited any detectable bone growth. Importantly, no adverse effects were reported during the study.
In July 2024, OBL announced a strategic partnership with a leading global animal health company to further develop treatments for periodontal disease in companion animals. Breitenbach emphasized that this collaboration will enhance animal health and raise awareness about oral health issues.
Periodontal disease is alarmingly common among dogs, affecting 80 to 90% of those over two years old. Smaller breeds are particularly susceptible, with incidence rates increasing with age. Symptoms of periodontal disease in dogs may include pawing at the mouth, drooling, reduced appetite, bad breath, and behavioral changes. Regular veterinary dental cleanings and proper home care are crucial for prevention.
Stella Vnook, president of Oral Biolife, reiterated the company’s mission to provide non-invasive dental care options. She expressed enthusiasm about the promising results from their research and plans to continue studying the safety and efficacy of Ambrilux Dental Gel.
Related topics: